Codexis, Inc. (CDXS) Stock Score, Valuation & Financial Research
Codexis, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 12/100.
Quick answer for CDXS
Codexis, Inc. currently has a Wall Street Score of 12/100. The stored market price is $1.47. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Codexis, Inc. does
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the
CDXS financial snapshot
- Wall Street Score:
- 12/100
- Current price:
- $1.47
- Market capitalization:
- $158.1M
- Revenue:
- $77.7M
- Net income:
- $-30.7M
- Free cash flow:
- $-23.8M
- Cash:
- $27.2M
- Total debt:
- $72.6M
- EPS:
- -0.34
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 15/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-23.8M, showing cash burn in the current stored period.
- The balance sheet shows $27.2M of cash versus $72.6M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CDXS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.